KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Consolidated Net Income (2017 - 2025)

Historic Consolidated Net Income for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to -$200.0 million.

  • Moderna's Consolidated Net Income fell 163846.15% to -$200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 billion, marking a year-over-year decrease of 4010.79%. This contributed to the annual value of -$3.6 billion for FY2024, which is 2445.91% up from last year.
  • According to the latest figures from Q3 2025, Moderna's Consolidated Net Income is -$200.0 million, which was down 163846.15% from -$825.0 million recorded in Q2 2025.
  • Moderna's 5-year Consolidated Net Income high stood at $4.9 billion for Q4 2021, and its period low was -$3.6 billion during Q3 2023.
  • In the last 5 years, Moderna's Consolidated Net Income had a median value of $79.0 million in 2023 and averaged $541.7 million.
  • As far as peak fluctuations go, Moderna's Consolidated Net Income skyrocketed by 247606.84% in 2021, and later plummeted by 163846.15% in 2025.
  • Moderna's Consolidated Net Income (Quarter) stood at $4.9 billion in 2021, then tumbled by 69.91% to $1.5 billion in 2022, then plummeted by 85.19% to $217.0 million in 2023, then plummeted by 616.13% to -$1.1 billion in 2024, then soared by 82.14% to -$200.0 million in 2025.
  • Its Consolidated Net Income was -$200.0 million in Q3 2025, compared to -$825.0 million in Q2 2025 and -$971.0 million in Q1 2025.